-
Product Insights
Relapsed Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Relapsed Multiple Myeloma Clinical Trial Report Overview A total of 1702 relapsed multiple myeloma clinical trials were conducted as of November 2024. The relapsed multiple myeloma clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · ...
-
Product Insights
Refractory Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Refractory Multiple Myeloma Clinical Trial Report Overview A total of 1726 refractory multiple myeloma clinical trials were conducted as of November 2024. The refractory multiple myeloma clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · ...
-
Product Insights
Burkitt Lymphoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Burkitt Lymphoma Clinical Trial Report Overview A total of 474 Burkitt lymphoma clinical trials were conducted as of November 2024. The Burkitt lymphoma clinical trial report provides a comprehensive understanding of the Burkitt lymphoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · North...
-
Sector Analysis
Bladder Cancer Epidemiology Analysis and Forecast to 2033
Bladder Cancer Report Overview In the 8MM, there were 2,79,419 diagnosed incident cases of bladder cancer in 2023. The diagnosed incident cases of bladder cancer will register an AGR of more than 2% during 2023-2033. Bladder cancer is a type of cancer that begins in the urinary bladder, most often in the urothelial cells lining the inside of the urinary bladder. Globally, it is the ninth most common type of cancer. Diagnosis of the disease is both challenging and expensive since...
-
Product Insights
Colorectal Cancer Screening Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Colorectal Cancer Screening Tests Pipeline Market Report Overview Colorectal cancer screening tests are carried out to monitor the bowel health of at-risk individuals, typically the elderly, to be able to detect and treat colorectal cancer in time. The Colorectal Cancer Screening Tests pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the...
-
Sector Analysis
Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Esophageal Cancer Marketed and Pipeline Drugs Report Overview Esophageal cancer (EC) is a malignant tumor in the esophagus’s inner layer (mucosa) and grows outside. The esophagus is a hollow, muscular tube that connects the throat to the stomach, facilitating the movement of food and aiding in digestion. EC is histologically classified as squamous cell carcinoma (SCC) and esophageal adenocarcinoma (EAC). The classification is based on the type of cell it starts in, which differs in its etiology, pathology, tumor location, therapeutics,...
-
Product Insights
Bone Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Bone Cancer Clinical Trial Report Overview A total of 1620 bone cancer clinical trials were conducted as of August 2024. The bone cancer clinical trial report provides a comprehensive understanding of the bone cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · ...
-
Sector Analysis
Renal Cell Carcinoma (RCC) Epidemiology Analysis and Forecast to 2033
Renal Cell Carcinoma (RCC) Report Overview In the 8MM, there were 199,400 diagnosed incident cases of RCC in 2023. The diagnosed incident cases of RCC will register an AGR of more than 1% during 2023-2033. Renal cell carcinoma (RCC) is a disease in which cancer cells are found in the lining of kidney tubules. Renal Cell Carcinoma (RCC) Market Outlook, 2023-2033 (Diagnosed Incident Cases) Buy the Full Report for More Insights into the Renal Cell Carcinoma (RCC) Market Forecast Download...
-
Sector Analysis
Chondrosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Chondrosarcoma therapeutics. • In 2024, more than 13,000 diagnosed incident cases of CS are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for CS. • Currently, no approved disease-modifying therapy is available globally in the market space for CS. • R&D activities for CS are moderate with 29 molecules in the pipeline, out of which Phase III holds only one drug, whereas Phase II...
-
Sector Analysis
Soft Tissue Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Soft Tissue Sarcoma (STS) Marketed and Pipeline Drugs Report Overview Soft tissue sarcoma (STS) encompasses more than 50 types of cancer that develop in the body's soft tissues, which include muscles, fat, and nerves. These tumors primarily occur in areas like the arms, legs, chest, or abdomen. Soft tissue sarcomas exhibit diverse subtypes, each displaying unique traits and behaviors. They can differ in terms of aggressiveness, rate of growth, and propensity to metastasize to distant organs. In 2024, 368,024 diagnosed...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.